Peter Goodfellow
Chairman chez Gammadelta Therapeutics Ltd.
Profil
Peter Goodfellow is currently the Chairman at Gammadelta Therapeutics Ltd., Adaptate Biotherapeutics Ltd., and Senior Advisor at Abingworth LLP.
Previously, he held positions as Director at deCODE genetics, Inc., Director at The Institute of Cancer Research: Royal Cancer Hospital, Director-Supervisory Board at Prosensa Holding NV, Director at Muscular Dystrophy Campaign Ltd., and Director at Virion Biotherapeutics Ltd.
He also served as Senior Vice President-Discovery Research at GSK Plc and as a Professor at the University of Cambridge.
Dr. Goodfellow obtained a doctorate degree from the University of Oxford and completed undergraduate and doctorate degrees at the University of Bristol.
Postes actifs de Peter Goodfellow
| Sociétés | Poste | Début |
|---|---|---|
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Chairman | - |
Adaptate Biotherapeutics Ltd.
 Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Chairman | - |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. | Consultant / Advisor | - |
Anciens postes connus de Peter Goodfellow
| Sociétés | Poste | Fin |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Director/Board Member | 21/06/2023 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Director/Board Member | 13/07/2010 |
| GSK PLC | Chief Tech/Sci/R&D Officer | - |
| University of Cambridge | Corporate Officer/Principal | - |
Virion Biotherapeutics Ltd.
 Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom. | Director/Board Member | - |
Formation de Peter Goodfellow
| University of Oxford | Doctorate Degree |
| University of Bristol | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GSK PLC | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Entreprise privées | 8 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
The Institute of Cancer Research: Royal Cancer Hospital
 The Institute of Cancer Research: Royal Cancer Hospital Miscellaneous Commercial ServicesCommercial Services The Institute of Cancer Research: Royal Cancer Hospital operates as a cancer research institution. The company was founded in 1909 and is headquartered in London, the United Kingdom. | Commercial Services |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth LLP is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. | Finance |
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
| Muscular Dystrophy Campaign Ltd. | |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Virion Biotherapeutics Ltd.
Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom. | Health Technology |
Adaptate Biotherapeutics Ltd.
Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Commercial Services |
